Knoblich JA, Jan LY, Jan YN. Asymmetric segregation of Numb and Prospero during cell division. Nature 1995; 377: 624–627.
Rhyu MS, Jan LY, Jan YN. Asymmetric distribution of numb protein during division of the sensory organ precursor cell confers distinct fates to daughter cells. Cell 1994; 76: 477–491.
Dho SE, French MB, Woods SA, McGlade CJ. Characterization of four mammalian numb protein isoforms. Identification of cytoplasmic and membrane-associated variants of the phosphotyrosine binding domain. J Biol Chem 1999; 274: 33097–33104.
Frise E, Knoblich JA, Younger-Shepherd S, Jan LY, Jan YN. The Drosophila Numb protein inhibits signaling of the Notch receptor during cell-cell interaction in sensory organ lineage. Proc Natl Acad Sci USA 1996; 93: 11925–11932.
McGill MA, McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 2003; 278: 23196–23203.
Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G et al. NUMB controls p53 tumour suppressor activity. Nature 2008; 451: 76–80.
George RM, Biressi S, Beres BJ, Rogers E, Mulia AK, Allen RE et al. Numb-deficient satellite cells have regeneration and proliferation defects. Proc Natl Acad Sci USA 2013; 110: 18549–18554.
Pece S, Confalonieri S, R Romano P, Di Fiore PP. NUMB-ing down cancer by more than just a NOTCH. Biochim Biophys Acta 2011; 1815: 26–43.
Dhami GK, Liu H, Galka M, Voss C, Wei R, Muranko K et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Mol Cell 2013; 50: 565–576.
Smith CA, Lau KM, Rahmani Z, Dho SE, Brothers G, She YM et al. aPKC-mediated phosphorylation regulates asymmetric membrane localization of the cell fate determinant Numb. EMBO J 2007; 26: 468–480.
Siddique HR, Feldman DE, Chen CL, Punj V, Tokumitsu H, Machida K. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer. Hepatology (Baltimore, Md) 2015; 62: 1466–1479.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307–310.
Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol 2010; 3: 1–12.
Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643–660.
Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279: 25549–25561.
Liu XS, Li H, Song B, Liu X. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep 2010; 11: 626–632.
Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O et al. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 2009; 284: 18588–18592.
Wang H, Ouyang Y, Somers WG, Chia W, Lu B. Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon. Nature 2007; 449: 96–100.
Schmit TL, Nihal M, Ndiaye M, Setaluri V, Spiegelman VS, Ahmad N. Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res 2012; 72: 3864–3872.
Shao T, Liu X. Identification of rictor as a novel substrate of Polo-like kinase 1. Cell Cycle 2015; 14: 755–760.
Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14: 3–15.
Nishimura T, Kaibuchi K. Numb controls integrin endocytosis for directional cell migration with aPKC and PAR-3. Dev Cell 2007; 13: 15–28.
Liu D, Cui L, Wang Y, Yang G, He J, Hao R et al. Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity. Hepatology (Baltimore, Md) 2016; 64: 390–404.
Zhang H, Diab A, Fan H, Mani SK, Hullinger R, Merle P et al. PLK1 and HOTAIR accelerate proteasomal degradation of SUZ12 and ZNF198 during hepatitis B virus-induced liver carcinogenesis. Cancer Res 2015; 75: 2363–2374.
Ang XL, Wade Harper J. SCF-mediated protein degradation and cell cycle control. Oncogene 2005; 24: 2860–2870.
Yogosawa S, Miyauchi Y, Honda R, Tanaka H, Yasuda H. Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochem Biophys Res Commun 2003; 302: 869–872.
Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol 1998; 18: 3974–3982.
Sczaniecka M, Gladstone K, Pettersson S, McLaren L, Huart AS, Wallace M. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem 2012; 287: 14052–14068.
Zhu K, Shan Z, Zhang L, Wen W. Phospho-Pon binding-mediated fine-tuning of Plk1 activity. Structure (London, England: 1993) 2016; 24: 1110–1119.
Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm 2014; 11: 2713–2719.
Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26: 2093–2108.